HEV study protocol : design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh

INTRODUCTION: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis in the developing world and is a public health problem, in particular among pregnant women, where it may lead to severe or fatal complications. A recombinant HEV vaccine, 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, C...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaman, K, Dudman, Susanne, Stene-Johansen, Kathrine, Qadri, Firdausi, Yunus, Md, Sandbu, Synne, Gurley, Emily S, Overbo, Joakim, Julin, Cathinka Halle, Dembinski, Jennifer Lynn, Nahar, Quamrun, Rahman, Anisur, Bhuiyan, Taufiqur R, Rahman, Mustafizur, Haque, Warda, Khan, Jahangir, Aziz, Asma, Khanam, Mahbuba, Streatfield, Peter Kim, Clemens, John D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044974/
https://www.ncbi.nlm.nih.gov/pubmed/31959609
http://dx.doi.org/10.1136/bmjopen-2019-033702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044974/
https://www.ncbi.nlm.nih.gov/pubmed/31959609
http://dx.doi.org/10.1136/bmjopen-2019-033702

Ejemplares similares